| KENNESAW, Ga., Dec. 5, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has received a transitional pass-through status C-Code from the Centers for Medicare & Medicaid Services ("CMS") for its EpiFix® Amniotic Membrane Allograft. EpiFix® has been assigned a pass-through status under Medicar...continued MDXG Orthopedic Prosthetic Healthcare |
Monday, December 5, 2011
MiMedx Group Receives HCPCS C-Code from Medicare for EpiFix( Reimbursement
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment